我们应用先上的GooglePlay由于不熟悉发布流程最开始app是由Google服务器生成签名并发布，后经测试无法登陆微信提示签名不一致才发现这个问题，后面我们升级使用了自己签名证书，但是此时从GooglePlay上下载的应用是包含两个签名的（https://source.android.com/docs/security/features/apksigning/v3?hl=zh-cn#proof-of-rotation-and-self-trusted-old-certs-structs），使用微信签名获取工具获取出来的签名还是与开放平台记录的签名不一致。 现在问题是我们上国内市场的话用的是我们自己的签名但是GooglePlay上的是Google的签名+我们自己的签名，所以希望官网能支持多个签名的配置方式

已经存在该名称的应用，基于应用名称唯一原则，请重新提交一个新名称。如果你认为已有名称侵犯了你的合法权益，可以进行侵权投诉 这个名称在我之前的个人账户下，现在把个人账户下 的移动应用删除了，准备转移到企业账户下，但是名字一直申请不成功，怎么办，不是说没有保护期吗？还是我需要多久才能重新使用这个名字？还是仍然有重名的名字在

我公司之前注册开放平台账号并且认证,创建了一个应用,后面团队调入一个新成立的子公司,开发微信支付功能, 以新公司的名义注册微信开放平台账号认证通过后,先是在原来的账号下删除了应用,然后再新账号创建同名称的应用,提示重复,请问该怎么解决呢? 已经存在该名称的应用，基于应用名称唯一原则，请重新提交一个新名称。如果你认为已有名称侵犯了你的合法权益，可以进行侵权投诉 原账号 bnqc-icvdevelop@bngrp.com 新账号 7swords-pay@bngrp.com

我们想改一下移动应用的   应用名称   想问下这个应用名称  有没有保护期  保护期是多长时间？

开放平台修改APP名称，原来的名称有没有保护期，保护期是多久？ 我们要注册一个新的开放平台账号，然后会注册一个同名的APP，会先把老账号APP名称修改掉，新账号用原来的APP名称。修改掉的APP名称有没有保护期，保护期是多久？

因为授权问题，原本已经创建好的一个移动应用需要迁移到另一个账号下，旧账号已经将创建的应用删除，但是新账号创建的时候一直提示应用名称被占用。担心进行侵权投诉会对旧账号以及旧账号下的其他应用有影响，要怎么解决 急！！！！！

我想从一个小程序直接跳转到同主体下的公众号主页，而不是跳到关注公众号的页面，能实现吗，怎么实现，谢谢。

有好几个客户小程序出现这样的情况，是什么原因呢？ 请求看一下什么原因：[图片] 最后一次聊是在2020年3月24号下午差不多2 点

Error: Parsing failed at character position 360 near "H1A1表达增加（p <0.05，n =" Parsing failed at character position 427 near "以克服TMZ诱导的化学抗性的理论基础。" <rich-text nodes="{{Helper.getLanguage(item.Content,values[1])}}" selectable="true" class="articleContent" /> [代码][[代码][代码]    [代码][代码]{[代码][代码]      [代码][代码]"Title": [[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"替莫唑胺通过上调PD-L1促进GBM细胞的免疫逃逸。",[代码][代码]          [代码][代码]"Temozolomide promotes immune escape of GBM cells via upregulating PD-L1."[代码][代码]        [代码][代码]][代码][代码]      [代码][代码]],[代码][代码]      [代码][代码]"Content": [[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"多形性胶质母细胞瘤（GBM）是最常见的恶性原发性脑肿瘤，预后不良，目前有效的治疗策略仍然有限。",[代码][代码]          [代码][代码]"Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor with poor prognosis, and currently effective therapeutic strategies are still limited."[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"虽然替莫唑胺（TMZ）常用于GBM治疗，其作用机制已得到很好的表征，但其副作用需要全面研究。",[代码][代码]          [代码][代码]"Although temozolomide (TMZ) is commonly used for GBM therapy and its mechanism was well characterized, while its side effects were required comprehensive investigation."[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"在本研究中，我们发现TMZ攻击的GBM细胞强烈抑制激活的外周血单核细胞（PBMC）中的促炎细胞因子表达，这依赖于增强的CD274转录（编码PD-L1），但不依赖于其他免疫检查点，",[代码][代码]          [代码][代码]"In the present study, we revealed that TMZ-challenged GBM cells strongly suppressed pro-inflammatory cytokines expression in activated periphery blood mononuclear cells (PBMC), which depended on enhanced transcription of CD274 (encoding PD-L1), but not other immune checkpoints,"[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"例如CD276，HVEM和galectin-9。",[代码][代码]          [代码][代码]"such as CD276, HVEM and galectin-9."[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"此外，在TMZ处理的GBM细胞中，膜PD-L1的丰度也增加。",[代码][代码]          [代码][代码]"Moreover, abundance of membranous PD-L1 was also increased in TMZ-treated GBM cells."[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"当短发夹RNA（shRNA）敲低PD-L1表达时，TMZ处理的GBM细胞对PBMC的抑制作用变弱，表明PD-L1对TMZ处理的GBM细胞的免疫抑制能力至关重要。",[代码][代码]          [代码][代码]"When PD-L1 expression was knocked down by short hairpin RNA (shRNA), inhibitory effect of TMZ-treated GBM cells on PBMC became weakened, suggesting that PD-L1 was crucial for immune inhibition capacity of TMZ-treated GBM cells."[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"另外，放线菌素D在TMZ攻击后降低GBM细胞中的PD-L1表达，表明PD-L1诱导发生在转录水平。",[代码][代码]          [代码][代码]"Additionally, actinomycin D reduced PD-L1 expression in GBM cells after TMZ challenge, indicating that PD-L1 induction occurred at transcriptional level."[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"免疫印迹结果表明STAT3信号传导参与TMZ介导的PD-L1诱导，并且使用STAT3抑制剂VI或STAT3shRNA观察到PD-L1的减毒表达。",[代码][代码]          [代码][代码]"The immunoblotting results demonstrated that STAT3 signaling was involved in TMZ-mediated PD-L1 induction, and attenuated expression of PD-L1 was observed using STAT3 inhibitor VI or STAT3 shRNA."[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"最后，动物研究表明，TMZ和PD-1抗体疗法的组合强烈抑制肿瘤生长并实现GBM小鼠的存活率提高。",[代码][代码]          [代码][代码]"Finally, the animal study showed that combination of TMZ and PD-1 antibody therapy strongly inhibited tumor growth and achieved the improved survival rate of GBM mice."[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"因此，本研究揭示了经典化疗药物TMZ促进GBM细胞免疫逃逸，即使TMZ联合PD-1抗体治疗也未进一步提高复发性GBM患者的生存率，与传统治疗方法相比，而我们的动物研究提供了证据表明TMZ的组合",[代码][代码]          [代码][代码]"Accordingly, this study revealed the classical chemotherapy drug TMZ promoted GBM cells immune escape, even TMZ combine with PD-1 antibody treatment not further improve survival ratio of recurrent GBM patients compared with traditional therapy methods, while our animal study provided evidence that combination of TMZ"[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"和PD-1抗体是治疗GBM的一种有前景的方法，这些相互矛盾的结果表明，提高PD-1抗体的递送效率可以发挥强大的联合治疗效果。",[代码][代码]          [代码][代码]"and PD-1 antibody was a promising way to treat GBM, these contradictory results indicate improving the PD-1 antibody delivery efficiency can exert strong combinational therapy outcomes."[代码][代码]        [代码][代码]][代码][代码]      [代码][代码]],[代码][代码]      [代码][代码]"UID": "31285949",[代码][代码]      [代码][代码]"Date": "2019-07-11",[代码][代码]      [代码][代码]"Links": {[代码][代码]        [代码][代码]"pubmed": "31285949",[代码][代码]        [代码][代码]"pmc": "PMC6610056"[代码][代码]      [代码][代码]},[代码][代码]      [代码][代码]"Authors": "Silu.Wang,Fuli.Yao,Xianghe.Lu,Qun.Li,Zhipeng.Su,Jong-Ho.Lee,Chengde.Wang,Linyong.Du",[代码][代码]      [代码][代码]"JournalTitle": "American journal of cancer research"[代码][代码]    [代码][代码]},[代码][代码]    [代码][代码]{[代码][代码]      [代码][代码]"Title": [[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"对EGFR抑制的抗性机制揭示了人GBM中的代谢脆弱性。",[代码][代码]          [代码][代码]"Mechanisms of resistance to EGFR inhibition reveal metabolic vulnerabilities in human GBM."[代码][代码]        [代码][代码]][代码][代码]      [代码][代码]],[代码][代码]      [代码][代码]"Content": [[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"表皮生长因子受体基因（EGFR）的扩增代表胶质母细胞瘤（GBM）中最常见的遗传病变之一，然而，靶向该信号传导途径的疗法在临床上失败。",[代码][代码]          [代码][代码]"Amplification of the epidermal growth factor receptor gene (EGFR) represents one of the most commonly observed genetic lesions in glioblastoma (GBM), however, therapies targeting this signaling pathway have failed clinically."[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"在这里，使用人类肿瘤，原发性患者来源的异种移植物（PDX）和GBM的鼠模型，我们证明EGFR抑制导致肿瘤细胞的侵袭增加。",[代码][代码]          [代码][代码]"Here, using human tumors, primary patient-derived xenografts (PDXs), and a murine model for GBM, we demonstrate that EGFR inhibition leads to increased invasion of tumor cells."[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"此外，EGFR抑制剂处理的GBM表现出改变的氧化应激，增加的脂质过氧化作用和产生有毒的脂质过氧化产物。",[代码][代码]          [代码][代码]"Further, EGFR inhibitor-treated GBM demonstrate altered oxidative stress, with increased lipid peroxidation, and generation of toxic lipid peroxidation products."[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"确定具有升高的醛脱氢酶（ALDH）水平的肿瘤细胞亚群包含在EGFR抑制剂处理的GBM中观察到的显着比例的侵袭性细胞。",[代码][代码]          [代码][代码]"A tumor cell subpopulation with elevated aldehyde dehydrogenase (ALDH) levels were determined to comprise a significant proportion of the invasive cells observed in EGFR inhibitor-treated GBM."[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"我们对新诊断的GBM中ALDH1A1蛋白的分析显示，在69％（35/51）的病例中可检测到ALDH1A1表达，但肿瘤细胞的百分比相对较低。",[代码][代码]          [代码][代码]"Our analysis of ALDH1A1 protein in newly diagnosed GBM revealed detectable ALDH1A1 expression in 69% (35/51) of the cases, but in relatively low percentages of tumor cells."[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"对EGFR抑制剂治疗前后配对的人GBM的分析显示EGFR扩增的肿瘤中ALDH1A1表达增加（p <0.05，n = 13个肿瘤对），并且在鼠GBM中ALDH1A1-高克隆比ALDH1A1对EGFR抑制更具抗性。",[代码][代码]          [代码][代码]"Analysis of paired human GBM before and after EGFR inhibitor therapy showed an increase in ALDH1A1 expression in EGFR-amplified tumors (p&lt;0.05, n=13 tumor pairs), and in murine GBM ALDH1A1-high clones were more resistant to EGFR inhibition than ALDH1A1"[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"低克隆。",[代码][代码]          [代码][代码]"-low clones."[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"我们的数据将ALDH水平鉴定为具有高侵袭能力，改变的氧化应激和对EGFR抑制的抗性的GBM细胞的生物标志物，并揭示其抑制应限制GBM侵袭的治疗靶标。",[代码][代码]          [代码][代码]"Our data identify ALDH levels as a biomarker of GBM cells with high invasive potential, altered oxidative stress, and resistance to EGFR inhibition, and reveal a therapeutic target whose inhibition should limit GBM invasion."[代码][代码]        [代码][代码]][代码][代码]      [代码][代码]],[代码][代码]      [代码][代码]"UID": "31270152",[代码][代码]      [代码][代码]"Date": "2019-07-23",[代码][代码]      [代码][代码]"Links": {[代码][代码]        [代码][代码]"pubmed": "31270152",[代码][代码]        [代码][代码]"pii": "1535-7163.MCT-18-1330",[代码][代码]        [代码][代码]"doi": "10.1158/1535-7163.MCT-18-1330"[代码][代码]      [代码][代码]},[代码][代码]      [代码][代码]"Authors": "Andrew.McKinney,Olle R.Lindberg,Jane R.Engler,Katharine Y.Chen,Anupam.Kumar,Henry.Gong,Kan V.Lu,Erin F.Simonds,Timothy F.Cloughesy,Linda M.Liau,Michael.Prados,Andrew W.Bollen,Mitchel S.Berger,Joseph T C.Shieh,C David.James,Theodore P.Nicolaides,William H.Yong,Albert.Lai,Monika E.Hegi,William A.Weiss,Joanna J.Phillips",[代码][代码]      [代码][代码]"JournalTitle": "Molecular cancer therapeutics"[代码][代码]    [代码][代码]},[代码][代码]    [代码][代码]{[代码][代码]      [代码][代码]"Title": [[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"替莫唑胺抗性原代GBM干细胞样细胞和复发性GBM的比较转录组学分析鉴定碳酸酐酶CA2基因作为抗性因子的上调。",[代码][代码]          [代码][代码]"Comparative Transcriptomic Analysis of Temozolomide Resistant Primary GBM Stem-Like Cells and Recurrent GBM Identifies Up-Regulation of the Carbonic Anhydrase <i>CA2</i> Gene as Resistance Factor."[代码][代码]        [代码][代码]][代码][代码]      [代码][代码]],[代码][代码]      [代码][代码]"Content": [[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"大约95％的胶质母细胞瘤（GBM）患者显示肿瘤复发，使他们的治疗选择有限，因为复发性肿瘤最常耐受一线化疗标准替莫唑胺（TMZ）。",[代码][代码]          [代码][代码]"About 95% of patients with Glioblastoma (GBM) show tumor relapse, leaving them with limited therapeutic options as recurrent tumors are most often resistant to the first line chemotherapy standard Temozolomide (TMZ)."[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"为了鉴定涉及TMZ抗性的分子途径，分离，表征和选择原代GBM干细胞样细胞（GSC）用于体外TMZ抗性。",[代码][代码]          [代码][代码]"To identify molecular pathways involved in TMZ resistance, primary GBM Stem-like Cells (GSCs) were isolated, characterized, and selected for TMZ resistance in vitro."[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"随后，进行RNA测序分析并显示在TMZ抗性干细胞样细胞中总共49个差异表达的基因（| log2倍变化|> 0.5并且调整的<p>  - 值<0.1）。",[代码][代码]          [代码][代码]"Subsequently, RNA sequencing analysis was performed and revealed a total of 49 differentially expressed genes (|log2-fold change| &gt; 0.5 and adjusted <i>p</i>-value &lt; 0.1) in TMZ resistant stem-like cells compared"[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"到他们匹配的DMSO对照细胞。",[代码][代码]          [代码][代码]"to their matched DMSO control cells."[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"在上调基因中，我们将碳酸酐酶2（CA2）鉴定为与胶质瘤恶性肿瘤和患者存活相关的候选基因。",[代码][代码]          [代码][代码]"Among up-regulated genes, we identified carbonic anhydrase 2 (CA2) as a candidate gene correlated with glioma malignancy and patient survival."[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"值得注意的是，我们描述了CA2不仅在TMZ抗性GSC中对mRNA和蛋白质水平的一致上调，而且在患者匹配的第一次出现和复发肿瘤的临床样本中也是如此。",[代码][代码]          [代码][代码]"Notably, we describe consistent up-regulation of CA2 not only in TMZ resistant GSCs on mRNA and protein level, but also in patient-matched clinical samples of first manifest and recurrent tumors."[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"与碳酸酐酶抑制剂乙酰唑胺（ACZ）共处理使细胞对TMZ诱导的细胞死亡敏感。",[代码][代码]          [代码][代码]"Co-treatment with the carbonic anhydrase inhibitor Acetazolamid (ACZ) sensitized cells to TMZ induced cell death."[代码][代码]        [代码][代码]],[代码][代码]        [代码][代码][[代码][代码]          [代码][代码]"累积地，我们的发现说明了CA2作为复发性GBM中的化学增敏靶标的潜力，并提供了治疗相关的抑制CA2以克服TMZ诱导的化学抗性的理论基础。",[代码][代码]          [代码][代码]"Cumulatively, our findings illustrate the potential of CA2 as a chemosensitizing target in recurrent GBM and provide a rationale for a therapy associated inhibition of CA2 to overcome TMZ induced chemoresistance."[代码][代码]        [代码][代码]][代码][代码]      [代码][代码]],[代码][代码]      [代码][代码]"UID": "31262047",[代码][代码]      [代码][代码]"Date": "2019-07-02",[代码][代码]      [代码][代码]"Links": {[代码][代码]        [代码][代码]"pubmed": "31262047",[代码][代码]        [代码][代码]"pii": "cancers11070921",[代码][代码]        [代码][代码]"doi": "10.3390/cancers11070921"[代码][代码]      [代码][代码]},[代码][代码]      [代码][代码]"Authors": "Ricarda.Hannen,Martin.Selmansberger,Maria.Hauswald,Axel.Pagenstecher,Andrea.Nist,Thorsten.Stiewe,Till.Acker,Barbara.Carl,Christopher.Nimsky,Jörg Walter.Bartsch",[代码][代码]      [代码][代码]"JournalTitle": "Cancers"[代码][代码]    [代码][代码]}[代码][代码]  [代码][代码]][代码]

RT 你好，请问小程序内是否会根据IP是否在国内使用bing，在国外使用heremap？请问在未来在海外和国内，对于海外地图是否会统一使用heremap？ 请问无论是否LBS服务是否申请了海外权限，对于地图的展示（包括marker）没有影响？也就是，只要不涉及到WebserviceAPI，则无需正式版海外LBS权限也可以正常给用户展示海外地图？ 感谢